S12 Ep13: Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD
OncLive On Air
by OncLive® On Air
3d ago
In today’s episode, supported by Takeda, we had the pleasure of speaking with Mark B. Geyer, MD, and Elias Jabbour, MD, about updates in the management of Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Geyer is the Adolescent and Young Adult Program leader and the Adult Lymphoblastic Leukemia Program leader in the Leukemia Service, as well as the chair of Quality Assessment in the Cellular Therapy Service at Memorial Sloan Kettering Cancer Center in New York, New York. Dr Jabbour is a professor in the Department of Leukemia in the Division of Cancer Medicine at Th ..read more
Visit website
S12 Ep12: Advances in RAS-Mutant PDAC Management Emphasize the Importance of Biomarker Testing: With Heinz-Josef Lenz, MD
OncLive On Air
by OncLive® On Air
1w ago
In today’s episode, supported by Revolution Medicines, we had the pleasure of speaking with Heinz-Josef Lenz, MD, about RAS mutations in pancreatic ductal adenocarcinoma (PDAC). Dr Lenz is a professor of medicine at the Keck School of Medicine of the University of Southern California (USC), as well as the J. Terrence Lanni Chair in Gastrointestinal Cancer Research, co-director of the USC Center for Molecular Pathway and Drug Discovery, and co-director of the USC Norris Center for Cancer Drug Development in Los Angeles. In our exclusive interview, Dr Lenz discussed the prevalence of RAS mutati ..read more
Visit website
S12 Ep11: How Academia and Industry Intersect to Improve Oncology Research and Patient Care: With D. Ross Camidge, MD, PhD; and Tim Eisen, MB BChir, PhD
OncLive On Air
by OncLive® On Air
1w ago
Drs Camidge and Eisen discussed Dr Eisen's dual career in academia and industry. Growing up in London, he pursued medicine, excelling in cell pathology at University College London, and later specialized in oncology at Cambridge. He joined Roche in 2020. Dr Eisen emphasized the importance of aligning academic and clinical strengths, advocating for industry experience to enhance drug development. He aims to foster interfaces between academia and industry, ensuring sustainable health research and training the next generation of drug developers ..read more
Visit website
S12 Ep10: Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD
OncLive On Air
by OncLive® On Air
1w ago
In today’s episode, supported by Ascentage Pharma, we had the pleasure of speaking with Elias Jabbour, MD, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Dr Jabbour discussed the 1.5-year follow-up data from a phase 1b trial (NCT04260022) investigating olverembatinib (HQP1351) in patients with heavily pretreated chronic-phase chronic myeloid leukemia (CML), enrollment considerations for the registrational phase 3 POLARIS-2 trial (NCT06423911) that is further evaluating th ..read more
Visit website
S12 Ep9: How Second Primary Cancer Risk Factors Into CAR T-Cell Therapy Considerations: With Saurabh Dahiya, MD, FACP; and Shyam A. Patel, MD, PhD
OncLive On Air
by OncLive® On Air
2w ago
Drs Dahiya and Patel discussed the pathobiology of SPCs that develop after CAR T-cell therapy, potential SPC prevention strategies, and how SPC research may help optimize CAR T-cell product development in the future ..read more
Visit website
S12 Ep8: How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD
OncLive On Air
by OncLive® On Air
2w ago
In today’s episode, we had the pleasure of speaking with David Gerber, MD, a professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center, a member of its Division of Hematology/Oncology, and co-director of Education and Training for the Harold C. Simmons Comprehensive Cancer Center in Dallas. In our exclusive interview, Dr Gerber discussed the evolving role of antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), focusing on findings from key clinical trials. He highlighted results from the phase 3 TROPION-Lung01 trial (NCT04656652 ..read more
Visit website
S12 Ep7: Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD
OncLive On Air
by OncLive® On Air
2w ago
In today’s episode, supported by Amgen, we had the pleasure of speaking with Ryan Cassaday, MD, an associate professor in the Clinical Research Division at the Fred Hutchinson Cancer Center and an associate professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle, Washington.  In our exclusive interview, Dr Cassaday discussed insights from several trials investigating blinatumomab (Blincyto) in patients with B-cell acute lymphoblastic leukemia (B-ALL) that were reported at the 2024 ASH Annual Meeting, including subgroup analyses o ..read more
Visit website
S12 Ep6: FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD
OncLive On Air
by OncLive® On Air
3w ago
In today’s episode, supported by Bristol Myers Squibb, we had the pleasure of speaking with Roxana S. Dronca, MD, about the FDA approval of subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig; subcutaneous nivolumab) for advanced or metastatic solid tumors. Dr Dronca is a professor of oncology, a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, and director of the Mayo Clinic Comprehensive Cancer Center in Jacksonville, Florida. On December 27, 2024, the FDA approved subcutaneous nivolumab across approved adult, solid tumor nivolumab indicati ..read more
Visit website
S12 Ep5: MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD
OncLive On Air
by OncLive® On Air
1M ago
In this episode of Oncology Unplugged, a podcast series from OncLive and MedNews Week, podcast host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, and Yan Leyfman, MD, a resident physician at Mount Sinai in New York, New York, discussed the origins and mission of MedNews Week, a global platform designed to combat health care misinformation and advance medical education. Conceived during the COVID-19 pandemic, MedNews Week was created in response to widespread misinformation and a need for accessible, evidence-based information. Over the past 2 and a ..read more
Visit website
S12 Ep4: Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD
OncLive On Air
by OncLive® On Air
1M ago
In today’s episode, we had the pleasure of speaking with Alec Watson, MD, a thoracic oncology fellow in the School of Medicine in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus in Aurora. In our exclusive interview, Dr Watson discussed the rationale for and key findings from a retrospective analysis examining the ways that oncogene overlap could identify clinically relevant thresholds for MET, KRAS, and HER2 gene copy number gain in non–small cell lung cancer; next steps for this research; and the future implications of these findings ..read more
Visit website

Follow OncLive On Air on FeedSpot

Continue with Google
Continue with Apple
OR